3,134 publications from this institution
The localized surface plasmon of a metal nanoparticle can influence the optical properties of a molecule in the plasmon field. In a previous study of molecular oxygen adjacent to nanodisks on a flat substrate, we showed that a plasmon field can increase the probability of the O <sub>2</sub>(a <sup>1</sup>Δ <sub>g</sub>) ← O <sub>2</sub>(X <sup>3</sup>Σ <sub>g</sub> <sup>-</sup>) radiative transition at 1275 nm. For the present study, we set out to ascertain if metal nanoparticles suspended in a liquid solvent could likewise induce measurable plasmonic effects on optical transitions in oxygen. Metal nanoparticles were prepared with the intent of selectively perturbing the 765 nm O <sub>2</sub>(X <sup>3</sup>Σ <sub>g</sub> <sup>-</sup>) → O <sub>2</sub>(b <sup>1</sup>Σ <sub>g</sub> <sup>+</sup>) absorption transition. Because O <sub>2</sub>(b <sup>1</sup>Σ <sub>g</sub> <sup>+</sup>) efficiently decays to O <sub>2</sub>(a <sup>1</sup>Δ <sub>g</sub>), we used the spectrally distinct O <sub>2</sub>(a <sup>1</sup>Δ <sub>g</sub>) ← O <sub>2</sub>(X <sup>3</sup>Σ <sub>g</sub> <sup>-</sup>) phosphorescent transition at 1275 nm to probe the potential plasmon effects at 765 nm. Although we indeed observed nanoparticle-mediated effects on the O <sub>2</sub>(X <sup>3</sup>Σ <sub>g</sub> <sup>-</sup>) → O <sub>2</sub>(b <sup>1</sup>Σ <sub>g</sub> <sup>+</sup>) transition, our present data are readily explained in terms of a nanoparticle-dependent change in the path length of light propagation through the sample. We modeled the latter using features of radiative transfer theory. As such, we cannot claim to observe a plasmonic effect on oxygen from these nanoparticles suspended in solution. Instead, our results point to the general importance of considering the effects of light scattering, certainly for experiments on suspended metal nanoparticles. Indeed, the extent to which light scattering can influence such optical experiments leads us to infer that many claims of a plasmonic effect could be misassigned.
The Air Cushion Vehicle (ACV, also called hovercraft) is greatly influenced by the environment when it is sailing at sea, and it has serious nonlinearity and large inertia. So it is difficult to establish accurate mathematical model. Because of the nonlinear mapping ability of neural networks, the neural network is used to identify the motion model of ACV. The comparison tests between the network model and the simulation model are carried out, and the results verify the feasibility of using the neural network to establish the aerodynamic model of ACV.
In resistant hypertension, ingesting one or more blood pressure (BP)-lowering medications at bedtime is associated with significant reduction of sleep-time BP, a sensitive prognostic marker of cardiovascular disease (CVD) risk. This randomized trial investigated if bedtime therapy with at least one hypertension medication exerts better BP control and CVD risk reduction than conventional, morning-time therapy with all medications. We conducted a prospective, open-label, blinded-endpoint trial on 776 patients (387 men/389 women) with resistant hypertension, 61.6 ± 11.2 (mean ± SD) yrs of age. Patients were randomized to ingest all their prescribed hypertension medications upon awakening or ≥1 of them at bedtime. BP was measured by ambulatory monitoring for 48 h at baseline, and again annually or more frequently (quarterly) if treatment adjustment was required. After a median follow-up of 5.4 yrs (range, .5-8.5 yrs), participants ingesting ≥1 hypertension medications at bedtime showed a significantly lower hazard ratio (HR) of total CVD events (adjusted by age, sex, and diabetes) than those ingesting all medications upon awakening (.38 [95% CI: .27-.55]; number of events 102 vs. 41; p < .001). The difference between groups in the adjusted HR of major CVD events (a composite of CVD death, myocardial infarction, ischemic stroke, and hemorrhagic stroke) was also statistically significant (.35 [95% CI: .18-.68]; number of events 32 vs. 12; p = .002). At the last evaluation, patients treated with the bedtime versus awakening-time-treatment regimen showed significantly lower sleep-time systolic/diastolic BP mean values (121.6/65.4 vs. 113.0/61.1 mm Hg; p < .001) and higher prevalence of controlled ambulatory BP (61% vs. 46%; p < .001). The progressive decrease in the sleep-time systolic BP mean during follow-up was the most significant predictor of event-free survival (15% risk reduction per 5 mm Hg decreased asleep systolic BP mean). Among patients with resistant hypertension, ingestion of at least one hypertension medication at bedtime, compared with all medications upon waking, resulted in improved ambulatory BP control and fewer hard and soft CVD events.
Torasemide is a high-ceiling loop diuretic frequently used in the treatment of congestive heart failure, renal failure, and hypertension. Low doses of torasemide (2.5 to 5 mg/day) do not elevate 24 h natriuresis, and they constitute effective monotherapy for mild-to-moderate uncomplicated essential hypertension according to results based on clinic blood pressure (BP). However, there has yet to be a proper evaluation of its 24 h efficacy or potential dependency of effects according to the circadian time of treatment. Accordingly, this trial investigated the administration time-dependent efficacy of torasemide in uncomplicated essential hypertensive patients. We studied a total of 113 grade 1 and 2 hypertensive patients, 51.7+/-10.6 yrs of age, randomly assigned to receive torasemide (5 mg/day) as a monotherapy either upon awakening or at bedtime. BP was measured by ambulatory monitoring for 48 consecutive hours before and after six weeks of treatment. The efficacy of torasemide was significantly greater with bedtime dosing (i.e., 14.8 and 9.5 mmHg reduction in the 24 h mean systolic and diastolic BP, respectively) as compared with morning dosing upon awakening (i.e., 6.4 and 3.4 mmHg reduction in mean systolic and diastolic BP; p<0.001 between the two treatment-time groups). The percentage of patients with controlled ambulatory BP after treatment was also higher after bedtime treatment (64 vs. 23%; p<0.001). Safety and tolerability were comparable between the two treatment-time groups. A dose of 5 mg/day torasemide is more effective for BP reduction for uncomplicated essential hypertensive patients when ingested at bedtime than in the morning upon arising. The difference in antihypertensive efficacy as a function of the circadian dosing-time of torasemide here documented should be taken into account when prescribing this loop diuretic to treat essential hypertensive patients.
Abstract The effective population size ( N e ) is a key parameter to quantify the magnitude of genetic drift and inbreeding, with important implications in human evolution. The increasing availability of high-density genetic markers allows the estimation of historical changes in N e across time using measures of genome diversity or linkage disequilibrium between markers. Selection is expected to reduce diversity and N e , and this reduction is modulated by the heterogeneity of the genome in terms of recombination rate. Here we investigate by computer simulations the consequences of selection (both positive and negative) and of recombination rate heterogeneity in the estimation of historical N e . We also investigate the relationship between diversity parameters and N e across the different regions of the genome using human marker data. We show that the estimates of historical N e obtained from linkage disequilibrium between markers ( N e LD ) are virtually unaffected by selection. In contrast, those estimates obtained by coalescence mutation-recombination-based methods can be strongly affected by it, what could have important consequences for the estimation of human demography. The simulation results are supported by the analysis of human data. The estimates of N e LD obtained for particular genomic regions do not correlate with recombination rate, nucleotide diversity, polymorphism, background selection statistic, minor allele frequency of SNPs, loss of function and missense variants and gene density. This suggests that N e LD measures are merely indicative of demographic changes in population size across generations. Author summary The inference of the demographic history of populations is of great relevance in evolutionary biology. This inference can be made from genomic data using coalescence methods or linkage disequilibrium methods. However, the assessment of these methods is usually made assuming neutrality (absence of selection). Here we show by computer simulations and analyses of human data that the estimates of historical effective population size obtained from linkage disequilibrium between markers are unaffected by natural selection, either positive or negative. In contrast, estimates obtained by coalescence mutation-recombination-based methods can be strongly affected by it, which could have important consequences for recent estimations of human demography. Thus, only linkage disequilibrium methods appear to provide unbiased estimates of the population census size.
A full-length cDNA encoding glutamate decarboxylase (designated as OsGAD3), which catalyzes the conversion of glutamate to gamma-aminobutyric acid (GABA), was isolated from the GABA-rich giant-embryo Oryza sativa (Shangshi Jing 315). The full-length cDNA of OsGAD3 (SSJ315) has a 1479 bp open reading frame (ORF) encoding a protein of 492 amino acid residues. The deduced protein had an isoelectric point (pI) of 5.72 and a calculated molecular weight of 56.1 kD. Sequence comparison showed that OsGAD3 (SSJ315) matches the glutamate decarboxylases of other plant species reported previously. Analysis of the structural features of the C-terminal portions of plant GADs revealed that OsGAD3 (SSJ315) has the typical CaM-binding domain (CaMBD) in the C-terminal region as most other plant GADs. Evolution analysis showed that plant GADs are conserved in the process of evolution. The cloning and characterization of the OsGAD3 (SSJ315) gene will enable us to use OsGAD3 to enhance GABA production in O. sativa (SSJ315) by metabolic engineering in the near future.
Dried leaves of Marchantia convoluta are largely used to \nprotect livers, and to treat tumefaction of skins in China. Flavonoids \nfrom Marchantia convoluta (MCF) were the active components against \nhepatitis B virus. In this study, the pharmacological properties of MCF \nconsisting of flavonoids determined by HPLC were examined in \nparticular. High dosage of MCF (20 and 40 μg/mL) could \nsignificantly reduce the activity of ALT and AST in the serum of mice \nwith acute hepatic injury caused by CCl4 and increase the contents of \nTP and ALP. MCF could inhibit the auricle tympanites of mice caused by \ndimethylbenzene. MCF inhibited obviously colibacillus, tyhoid bacillus, \nStaphylococcus aureus , bacillus enteritidis, hemolytic \nstreptococci type B and Diplococcus pneumoniae . The results \nshowed that MCF possess distinct effect of antibiosis, \nanti-inflammation and diuresis in mice.
Resumen es: Se han determinado una serie de parametros de calidad de la leche (% de proteinas, grasa, solidos no grasos y lactosa, asi como niveles de acidez en g/1...